PSMA is expressed at a very low level in normal prostatic tissues and non-prostatic tissues, but its expression in prostate cancer (Pca) tissues increases by 100–1000 times compared to that in normal tissues (64).This distribution characteristic has attracted attention to tumor therapy targeting PSMA. This evidence concerns the gene FOLH1 and posterior cortical atrophy.